Deciphering FFAR4 Mediated Functional Pathways and Potential Drug Targets in Diabetes Mellitus: An Integrated Protein Interaction Network Analysis and Kinetic Simulation

Authors

DOI:

https://doi.org/10.25004/IJPSDR.2024.160313

Keywords:

Type 2 Diabetes, FFAR4, Regulatory Network, biological pathway, kinetic simulation

Abstract

Type 2 Diabetes is a metabolic disorder that affects people worldwide. The G-protein coupled receptor (GPCR) known as free fatty acid receptor 4 (FFAR4) has been shown to be a potential therapeutic target for type 2 diabetes mellitus (T2DM)and complications linked to obesity. The present study focuses on the pharmaceutical role of FFAR4 and its potential agonists by predicting anti-diabetic responses, including insulin secretion, glucose uptake and calcium ion concentration levels. We identified differentially expressed genes and elucidated their role extensively through analysis of pathways, molecular mechanisms and linked biological processes. In the present study, a systems biology approach was implemented to establish an interaction network between FFAR4 and its driver’s such as CASR and NR1H4, that highlighted their significance as potential prognostic and therapeutic targets. A mathematical model incorporating biological events mediated by these proteins is studied and simulated using kinetics law reactions. Furthermore, the kinetic simulations were conducted to assess the impact of drug molecules, namely comp35, comp50, compN1 and compN2, on FFAR4 function. The findings reveal FFAR4’s potential as a therapeutic target for the treatment of type 2 diabetes mellitus.

Downloads

Download data is not yet available.

References

Ogurtsova K, Guariguata L, Barengo NC, Ruiz PLD, Sacre JW, Karuranga S, et al. IDF diabetes Atlas: Global estimates of undiagnosed diabetes in adults for 2021. Diabetes Research and Clinical Practice. 2022;183:109118. Available from: doi.org/10.1016/j.diabres.2021.109118.

Marcotte BV, Cormier H, Rudkowska I, Lemieux S, Couture P, Vohl MC. Polymorphisms in FFAR4 (GPR120) gene modulate insulin levels and sensitivity after fish oil supplementation. Journal of Personalized Medicine. 2017;7(4):15. Available from: doi.org/10.3390/jpm7040015.

Milligan G, Alvarez-Curto E, Hudson BD, Prihandoko R, Tobin AB. FFA4/GPR120: Pharmacology and Therapeutic Opportunities.Trends in Pharmacological Sciences. 2017;38(9):809–21. Available from: doi.org/10.1016/j.tips.2017.06.006.

Oh DY, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR, et al. A Gpr120-selective agonist improves insulin resistance and chronic inflammation in obese mice. Nature Medicine. 2014;20(8):942–7. Available from: doi.org/10.1038/nm.3614.

Suzuki K, Hatzikotoulas K, Southam L, Taylor HJ, Yin X, Lorenz KM, et al. Genetic drivers of heterogeneity in type 2 diabetes pathophysiology. Nature. 2024;627(8003):347–57. Available from: doi.org/10.1038/s41586-024-07019-6.

Liu S, Liu J, Yu Z, Qiu X, Jiang R, Li W. Multi-omics regulatory networks reveal the key driver genes in the development of type 2 diabetes. 2022;PPR:535552. Available from: doi.org/10.21203/rs.3.rs-1969297/v1.

Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Research. 2015;43(7):e47. Available from: doi.org/10.1093/nar/gkv007.

Kanehisa M, Furumichi M, Sato Y, Kawashima M, Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Research. 2023;51(D1): D587–92. Available from: doi.org/10.1093/nar/gkac963.

Rigden DJ, Fernández XM. The 2018 Nucleic Acids Research database issue and the online molecular biology database collection. Nucleic Acids Research. 2018;46(D1):D1–7. Available from: doi.org/10.1093/nar/gkx1235.

Bader GD, Hogue CWV. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4:2. Available from: doi.org/10.1186/1471-2105-4-2.

Funahashi A, Morohashi M, Kitano H, Tanimura N. CellDesigner: a process diagram editor for gene-regulatory and biochemical networks. Biosilico. 2003;1(5):159–62. Available from: doi.org/10.1016/s1478-5382(03)02370-9.

COPASI. COPASI. copasi.org. 2015.

Wang G, Liang R, Liu T, Wang L, Zou J, Liu N, et al. Opposing effects of il-1β/cox-2/pge2 pathway loop on islets in type 2 diabetes mellitus. Endocrine Journal. 2019;66(8): 691–9. Available from: doi.org/10.1507/endocrj.EJ19-0015.

Davegårdh C, Säll J, Benrick A, Broholm C, Volkov P, Perfilyev A, et al. VPS39-deficiency observed in type 2 diabetes impairs muscle stem cell differentiation via altered autophagy and epigenetics. Nature Communications. 2021;12(1):2431. Available from: doi.org/10.1038/s41467-021-22068-5.

Corbi SCT, de Vasconcellos JF, Bastos AS, Bussaneli DG, da Silva BR, Santos RA, et al. Circulating lymphocytes and monocytes transcriptomic analysis of patients with type 2 diabetes mellitus, dyslipidemia and periodontitis. Scientific Reports. 2020;10(1):8145. Available from: doi.org/10.1038/s41598-020-65042-9.

De Souza A, Irfan K, Masud F, Saif MW. Diabetes Type 2 and Pancreatic Cancer: A History Unfolding. JOP : Journal of the pancreas. 2016;17(2): 144–8. PMID: 29568247.

Alfadul H, Sabico S, Al-Daghri NM. The role of interleukin-1β in type 2 diabetes mellitus: A systematic review and meta-analysis. Frontiers in Endocrinology. 2022;13:901616. Available from: doi.org/10.3389/fendo.2022.901616.

Wang Y, Zhao M, Zhang Y. Identification of fibronectin 1 (FN1) and complement component 3 (C3) as immune infiltration-related biomarkers for diabetic nephropathy using integrated bioinformatic analysis. Bioengineered. 2021;12(1):5386–401. Available from: doi.org/10.1080/21655979.2021.1960766.

Adams GL, Velazquez F, Jayne C, Shah U, Miao S, Ashley ER, et al. Discovery of chromane propionic acid analogues as selective agonists of GPR120 with in Vivo activity in rodents. ACS Medicinal Chemistry Letters. 2017;8(1):96–101. Available from: doi.org/10.1021/acsmedchemlett.6b00394.

Winters MP, Sui Z, Wall M, Wang Y, Gunnet J, Leonard J, et al. Discovery of N-arylpyrroles as agonists of GPR120 for the treatment of type II diabetes. Bioorganic and Medicinal Chemistry Letters. 2018;28(5):841–6. Available from: doi.org/10.1016/j.bmcl.2018.02.013.

Jhinjharia D, Kaushik AC, Sahi S. A high-throughput structural dynamics approach for identification of potential agonists of FFAR4 for type 2 diabetes mellitus therapy. Journal of Biomolecular Structure and Dynamics. 2023;1–21. Available from: doi.org/10.1080/07391102.2023.2280707.

Sun Y, Qu J, Wang J, Zhao R, Wang C, Chen L, et al. Clinical and Functional Characteristics of a Novel KLF11 Cys354Phe Variant Involved in Maturity-Onset Diabetes of the Young. Journal of Diabetes Research. 2021;2021:7136869 Available from: doi.org/10.1155/2021/7136869.

Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, Miyauchi S, et al. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proceedings of the National Academy of Sciences of the United States of America. 2011;108(19):8030–5. Available from: doi.org/10.1073/pnas.1016088108.

Varney MJ, Benovic JL. The Role of G Protein–Coupled Receptors and Receptor Kinases in Pancreatic β-Cell Function and Diabetes. Pharmacological Reviews. 2024;76(2): 267–99. Available from: doi.org/10.1124/pharmrev.123.001015.

Stuttgen GM, Sahoo D. Ffar4: A new player in cardiometabolic disease? Endocrinology (United States). 2021;162(8). Available from: doi.org/10.1210/endocr/bqab111.

Hendy GN, Canaff L. Calcium-sensing receptor, proinflammatory cytokines and calcium homeostasis.Seminars in Cell and Developmental Biology. 2016;49:37–43. Available from: doi.org/10.1016/j.semcdb.2015.11.006.

Mamillapalli R, Wysolmerski J. The calcium-sensing receptor couples to Gαs and regulates PTHrP and ACTH secretion in pituitary cells. Journal of Endocrinology. 2010;204(3):287–97. Available from: doi.org/10.1677/JOE-09-0183.

Huang C, Miller RT. The calcium-sensing receptor and its interacting proteins: Ca2+ Sensing Receptor Review Series. Journal of Cellular and Molecular Medicine. 2007;11(5): 923–34. Available from: doi.org/10.1111/j.1582-4934.2007.00114.x.

Wang Y, Gao P, Wei C, Li H, Zhang L, Zhao Y, et al. Calcium sensing receptor protects high glucose-induced energy metabolism disorder via blocking gp78-ubiquitin proteasome pathway. Cell Death and Disease. 2017;8(5):e2799–e2799. Available from: doi.org/10.1038/cddis.2017.193.

Ravnskjaer K, Madiraju A, Montminy M. Role of the cAMP pathway in glucose and lipid metabolism. Handbook of Experimental Pharmacology. 2015;233 29–49. Available from: doi.org/10.1007/164_2015_32.

Li Z, Li Y, Overstreet JM, Chung S, Niu A, Fan X, et al. Inhibition of epidermal growth factor receptor activation is associated with improved diabetic nephropathy and insulin resistance in type 2 diabetes. Diabetes. 2018;67(9):1847–57. Available from: doi.org/10.2337/db17-1513.

Akash MSH, Rehman K, Liaqat A. Tumor Necrosis Factor-Alpha: Role in Development of Insulin Resistance and Pathogenesis of Type 2 Diabetes Mellitus. Journal of Cellular Biochemistry. 2018;119(1):105–10. Available from: doi.org/10.1002/jcb.26174.

Böni-Schnetzler M, Boller S, Debray S, Bouzakri K, Meier DT, Prazak R, Kerr-Conte J,et al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressed interleukin-1 receptor I. Endocrinology. 2009;150(12):5218–29. Availablefrom: doi.org/10.1210/en.2009-0543.

Yang J, Chi Y, Burkhardt BR, Guan Y, Wolf BA. Leucine metabolism in regulation of insulin secretion from pancreatic beta cells. Nutrition Reviews. 2010;68(5): 270–9. Available from: doi.org/10.1111/j.1753-4887.2010.00282.x.

Ehses JA, Perren A, Eppler E, Ribaux P, Pospisilik JA, Maor-Cahn R, et al. Increased number of islet-associated macrophages in type 2 diabetes. Diabetes. 2007;56(9): 2356–70. Available from: doi.org/10.2337/db06-1650.

Akash MSH, Shen Q, Rehman K, Chen S. Interleukin-1 receptor antagonist: A new therapy for type 2 diabetes mellitus. Journal of Pharmaceutical Sciences. 2012;101(5): 1647–58. Available from: doi.org/10.1002/jps.23057.

Tsalamandris S, Antonopoulos AS, Oikonomou E, Papamikroulis GA, Vogiatzi G, Papaioannou S, et al. The role of inflammation in diabetes: Current concepts and future perspectives. European Cardiology Review. 2019;14(1):50–9. Available from: doi.org/10.15420/ecr.2018.33.1.

Evangelakos I, Heeren J, Verkade E, Kuipers F. Role of bile acids in inflammatory liver diseases.Seminars in Immunopathology. 2021;43(4):577–90. Available from: doi.org/10.1007/s00281-021-00869-6.

Stofan M, Guo GL. Bile Acids and FXR: Novel Targets for Liver Diseases. Frontiers in Medicine. 2020;7:544. Available from: doi.org/10.3389/fmed.2020.00544.

Renga B, Mencarelli A, Vavassori P, Brancaleone V, Fiorucci S. The bile acid sensor FXR regulates insulin transcription and secretion. Biochimica et Biophysica Acta - Molecular Basis of Disease. 2010;1802(3):363–72.Available from: doi.org/10.1016/j.bbadis.2010.01.002.

Düfer M, Hörth K, Wagner R, Schittenhelm B, Prowald S, Wagner TFJ, et al. Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K ATP channel inhibition. Diabetes. 2012;61(6):1479–89. Available from: doi.org/10.2337/db11-0815.

Li L, Zhao H, Chen B, Fan Z, Li N, Yue J, et al. FXR activation alleviates tacrolimus-induced post-Transplant diabetes mellitus by regulating renal gluconeogenesis and glucose uptake. Journal of Translational Medicine. 2019;17(1):418. Available from: doi.org/10.1186/s12967-019-02170-5.

Ram C, Jha AK, Ghosh A, Gairola S, Syed AM, Murty US, et al. Targeting NLRP3 inflammasome as a promising approach for treatment of diabetic nephropathy: Preclinical evidences with therapeutic approaches.European Journal of Pharmacology. 2020;885. Available from: doi.org/10.1016/j.ejphar.2020.173503.

Chen H, Zhang X, Liao N, Ji Y, Mi L, Gan Y, et al. Identification of NLRP3 inflammation-related gene promoter hypomethylation in diabetic retinopathy. Investigative Ophthalmology and Visual Science. 2020;61(13):12. Available from: doi.org/10.1167/IOVS.61.13.12.

Luo B, Li B, Wang W, Liu X, Xia Y, Zhang C, et al. NLRP3 gene silencing ameliorates diabetic cardiomyopathy in a type 2 diabetes rat model. PLoS ONE. 2014;9(8):e104771. Available from: doi.org/10.1371/journal.pone.0104771.

Gelbach PE, Zheng D, Fraser SE, White KL, Graham NA, Finley SD. Kinetic and data-driven modeling of pancreatic β-cell central carbon metabolism and insulin secretion. PLoS Computational Biology. 2022;18(10):e1010555. Available from: doi.org/10.1371/journal.pcbi.1010555.

Deepa Maheshvare M, Raha S, König M, Pal D. A pathway model of glucose-stimulated insulin secretion in the pancreatic β-cell. Frontiers in Endocrinology. 2023;14:1185656. Available from: doi.org/10.3389/fendo.2023.1185656.

König M, Holzhütter HG. Kinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy. Journal of Biological Chemistry. 2012;287(44):36978–89. Available from: doi.org/10.1074/jbc.M112.382069.

Downloads

Published

30-05-2024

Issue

Section

Research Article

How to Cite

“Deciphering FFAR4 Mediated Functional Pathways and Potential Drug Targets in Diabetes Mellitus: An Integrated Protein Interaction Network Analysis and Kinetic Simulation”. International Journal of Pharmaceutical Sciences and Drug Research, vol. 16, no. 3, May 2024, pp. 412-25, https://doi.org/10.25004/IJPSDR.2024.160313.